Kenneth A. Stauderman
Known title: Chief Scientific OfficerCIK: 0001969388
Kenneth A. Stauderman's purchase track record
Kenneth A. Stauderman has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/28/2025 | CALC | $4K | -18.3% | +40.7% | +8.8% |
| 7/1/2025 | CALC | $2K | +97.2% | +267.3% | +11.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CALC | ▲ Buy | Open Market | 1,000 | $4K | 7/28/2025 | View on chart |
| CALC | ▼ Sell | Open Market | 1,000 | $4K | 7/25/2025 | View on chart |
| CALC | ▲ Buy | Open Market | 1,000 | $2K | 7/1/2025 | View on chart |
| CALC | ▲ Buy | Grant | 11,944 | — | 3/20/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
CALC files prospectus supplement for $25M ATM offering
CalciMedica has filed a prospectus supplement to conduct an at‑the‑market offering of up to $25 million of common stock. The filing indicates the company is seeking additional capital through a public offering. The stock currently trades near its $0.59 support level, and the neutral RSI suggests no strong momentum at present. The raise could provide funding for operations but may also dilute existing shareholders.
CALC files prospectus supplement for $25M ATM offering. CalciMedica has filed a prospectus supplement to conduct an at‑the‑market offering of up to $25 million of common stock. The filing indicates the company is seeking additional capital through a public offering. The stock currently trades near its $0.59 support level, and the neutral RSI suggests no strong momentum at present. The raise could provide funding for operations but may also dilute existing shareholders.